One of America’s Richest Families Emerges From Medline Deal
(Bloomberg) -- The sale of Medline Industries Inc. to a consortium of private equity firms has brought one of the world's wealthiest families into the limelight.
The deal, valued at more than $30 billion, stands to rank among the biggest transactions ever involving a family-owned business. The proceeds from the majority investment by Blackstone Group Inc., Carlyle Group Inc. and Hellman & Friedman will largely flow to the Mills, a Chicago-based clan who've been in the medical supply business for four generations.
While the private equity group will take a majority stake in Medline, the Mills family will keep their leadership roles at the company and remain its largest single shareholder. The Mills will retain at least 20% of the company, said a person familiar with the deal, who asked not to be named because the details are private.
The family may be worth about $30 billion, giving them a fortune akin to the Pritzkers, according to the Bloomberg Billionaires Index.
A Medline spokeswoman didn't return a call seeking comment.
“Making healthcare run better has been our focus for decades,” said Charlie Mills, Medline's chief executive officer in a statement Saturday. “This investment from some of the world's most experienced and successful private investment firms will enable us to accelerate that strategy while preserving the family-led culture that is core to our success.”
Read More: Blackstone, Carlyle, H&F to Buy Majority Stake in Medline
The deal comes as soaring valuations and a potential looming hike in the capital gains tax rate prompt more families to consider selling their businesses. Private-equity firms are armed with cheap debt and are sitting on trillions of dollars to invest.
Baby Blankets
At least eight buyout firms last month had been preparing offers for Medline, some attracted by the chance to trim costs and maximize profits at a company that's never been touched by another private-equity firm.
For the Mills, it unlocks a fortune bolstered in the past year by soaring demand for medical products amid the pandemic. The Northfield, Illinois-based company had $17.5 billion in revenue in 2020, up more than 25% from the year prior, according to trade publication Medical Design & Outsourcing.
Medline makes, sells and distributes more than half a million different kinds of medical products, including wheelchairs, urine-sample cups, face masks and anesthesia kits. The company makes the ubiquitous striped swaddling blanket that almost every U.S. hospital-born newborn is wrapped in and own brands such as Curad bandages.
The company's roots trace to 1910 when A.L. Mills, the great-grandfather of CEO Charlie Mills, started making butcher's aprons for Chicago slaughterhouses. He shifted to surgeon's gowns and nurses' uniforms after nuns at a nearby hospital sought his help. His son, Irving, joined the family business -- Mills Hospital Supply -- and oversaw the company's expansion into medical textiles.
Irving's sons James and Jon formed Medline in 1966. The second-generation leadership team of Charlie -- son of James, who died in 2019 -- his cousin Andy, now president, and Andy's brother-in-law, Jim Abrams, current chief operating officer, were elevated to their roles in 1997.
Massive Windfalls
While the Mills will still be closely involved in running the business and setting strategy, the deal will be transformational for a family that's been focused on their operating business for generations and is relatively low-profile and little-known outside of Illinois.
Other families who've had massive windfalls, including the Pritzkers, have stepped up their philanthropic activities, become players on the national political scene and plowed money into venture capital and private equity to increase their wealth.
Whatever their plans, the deal will accelerate the need for rigorous planning, according to Samy Dwek, a consultant to high-net worth families at The Family Office Doctor.
“In this case Charlie and Andy may want to consider splitting the assets to ensure smoother transition for each of their respective families,” he said. “They are about to face some hard decisions.”
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.